Top Markets
#1 Merlin's Seal BTC Merlin's Seal BTC +41.70%
#2 0G 0G +28.35%
#3 Fake World Assets Fake World Assets +21.19%
#4 Nockchain Nockchain +19.03%
#5 Full Moon Full Moon +17.70%
#6 Zora Zora +17.60%
#7 SAFEcoin SAFEcoin +17.38%
#8 Notcoin Notcoin +16.69%
#9 Axelar Axelar +15.62%
#10 ADO Protocol ADO Protocol +15.45%
Coin of the day
Merlin's Seal BTC Merlin's Seal BTC
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Kyverna Therapeutics, Inc. Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc.

KYTX
Classificação em ações #13173
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses... Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Preço da ação
$8.46
Última sincronização: 2026-08-28
Valor de mercado
$514.33M
Variação (1 dia)
-2.08%
Variação (1 ano)
128.03%
País
US
Negociar Kyverna Therapeutics, Inc. (KYTX)

Categoria

Healthcare
Lucros da Kyverna Therapeutics, Inc. (KYTX)
Lucros em 2026 TTM: 0
De acordo com os últimos relatórios financeiros da Kyverna Therapeutics, Inc., os ganhos atuais da empresa são de 0. Em 2026, a empresa teve ganhos de 0, igual a aos ganhos de 2026, que foram de 0. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Kyverna Therapeutics, Inc. de 2026 a 2026
Lucros no final de cada ano
Ano Lucros Alterar
Não há dados suficientes para as datas fornecidas.
Lucros de empresas semelhantes ou concorrentes
Empresa Lucros Diferença de Lucros País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH